Human variability in CYP3A4 metabolism and CYP3A4-related uncertainty factors for risk assessment

被引:69
作者
Dorne, JLCM [1 ]
Walton, K [1 ]
Renwick, AG [1 ]
机构
[1] Univ Southampton, Clin Pharmacol Grp, Southampton SO16 7PX, Hants, England
关键词
human variability; pharmacokinetics; CYP3A4; uncertainty factors; risk assessment; sensitive subgroups;
D O I
10.1016/S0278-6915(02)00209-0
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
CYP3A4 constitutes the major liver cytochrome P450 isoenzyme and is responsible for the oxidation of more than 50% of all known drugs. Human variability in kinetics for this pathway has been quantified using a database of 15 compounds metabolised extensively (>60%) by this CYP isoform in order to develop CYP3A4-related uncertainty factors for the risk assessment of environmental contaminants handled via this route. Data were analysed from published pharmacokinetic studies (after oral and intravenous dosing) in healthy adults and other subgroups using parameters relating primarily to chronic exposure [metabolic and total clearances, area under the plasma concentration-time curve (AUC)] and acute exposure (Cmax). Interindividual variability in kinetics was greater for the oral route (46%, 12 compounds) than for the intravenous route (32%, 14 compounds). The physiological and molecular basis for the difference between these two routes of exposure is discussed. In relation to the uncertainty factors used for risk assessment, the default kinetic factor of 3.16 would be adequate for adults, whereas a CYP3A4-related factor of 12 would be required to cover up to 99% of neonates, which have lower CYP3A4 activity. (C) 2003 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:201 / 224
页数:24
相关论文
共 271 条
[1]   LIDOCAINE DISPOSITION IN OBESITY [J].
ABERNETHY, DR ;
GREENBLATT, DJ .
AMERICAN JOURNAL OF CARDIOLOGY, 1984, 53 (08) :1183-1186
[2]   Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam [J].
Ahonen, J ;
Olkkola, KT ;
Neuvonen, PJ .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 51 (05) :415-419
[3]   ETHNIC-DIFFERENCES IN THE PHARMACOKINETICS OF ORAL NIFEDIPINE [J].
AHSAN, CH ;
RENWICK, AG ;
MACKLIN, B ;
CHALLENOR, VF ;
WALLER, DG ;
GEORGE, CF .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 31 (04) :399-403
[4]   THE INFLUENCES OF DOSE AND ETHNIC-ORIGINS ON THE PHARMACOKINETICS OF NIFEDIPINE [J].
AHSAN, CH ;
RENWICK, AG ;
WALLER, DG ;
CHALLENOR, VF ;
GEORGE, CF ;
AMANULLAH, M .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 54 (03) :329-338
[5]  
Aitchison J., 1966, The Lognormal Distribution: With Special Reference to Its Uses in Economics
[6]  
Amchin J, 1998, PSYCHOPHARMACOL BULL, V34, P211
[7]   INTERSUBJECT AND DOSE-RELATED VARIABILITY AFTER INTRAVENOUS ADMINISTRATION OF ERYTHROMYCIN [J].
AUSTIN, KL ;
MATHER, LE ;
PHILPOT, CR ;
MCDONALD, PJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1980, 10 (03) :273-279
[8]   MIDAZOLAM KINETICS IN WOMEN OF 2 AGE-GROUPS [J].
AVRAM, MJ ;
FRAGEN, RJ ;
CALDWELL, NJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1983, 34 (04) :505-508
[9]  
Azuma J, 1996, JPN PHARMACOL THER, V24, P267
[10]  
BACKMAN JT, 1994, EUR J CLIN PHARMACOL, V46, P551